FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

ND EXCHANGE COMMISSION
C. 20549

OMB APPROVAL

OMB Number: 3235-02

Estimated average burden

OMB Number:	3235-0287
Estimated average burd	den
hours per response:	0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Ramachandra Sumant  (Last) (First) (Middle)  C/O SYNTA PHARMACEUTICALS CORP.  45 HARTWELL AVENUE  (Street)  LEXINGTON MA 02421							2. Issuer Name and Ticker or Trading Symbol SYNTA PHARMACEUTICALS CORP [ SNTA ]  3. Date of Earliest Transaction (Month/Day/Year) 03/11/2013  4. If Amendment, Date of Original Filed (Month/Day/Year)								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title Other (specify below)  President, R&D  6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person					
(City) (State) (Zip)																				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea					ear) i	2A. Deemed Execution Date, if any (Month/Day/Year)			ransacti ode (Ins )		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			and 5) Securiti Benefic Owned		es ally	Form (D) o Indir	n: Direct r I ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								С	ode V		Amount	(A) or (D)	Price	F	Following Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)			
Common Stock 03/11/2013							3		A		75,000(1)	00 <sup>(1)</sup> A \$0.0		(1)	75,000			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
					· •	s, cal	<del></del>							_					1	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Exec if an	cution Date,	4. Transa Code 8)				Expiration (Month/Day			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	s S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
						v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares							
Employee Stock Option (Right to Buy)	\$9.59	03/11/2013			A		225,000		(2)	)	03/11/2023	Common	225,000		\$0	225,00	00	D		

## Explanation of Responses:

- 1. Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 50% of the shares on each of March 11, 2015 and March 11, 2016, provided the Reporting Person remains employed by the Issuer on such date.
- 2. The option vests as to 25% of the shares on March 11, 2014 and as to an additional 6.25% of the shares on the last day of each successive three-month period thereafter.

/s/ Adisty Wilson, Attorneyin-Fact 03/13/2013

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.